PharmaResearch Completes Five-Market Western Europe Roadshow for REJURAN

Strong industry interest across Benelux, the UK and Switzerland supports REJURAN’s phased expansion across Europe

SEOUL, South Korea, May 13, 2026 — PharmaResearch Co., Ltd., the South Korean regenerative medicine company behind the REJURAN, has completed a five-market Western Europe roadshow for REJURAN, its PN-based skin booster, as it expands the brand’s footprint across the region.

As REJURAN begins its Western European rollout, the roadshow served as a platform to introduce healthcare practitioners (HCPs) to PharmaResearch’s DNA Optimizing Technology (DOT™) based technology and its clinical use cases. The company said that the events drew strong interest from the industry, with attendees raising detailed questions about the product’s characteristics and practical applications.

The roadshow opened with a Benelux symposium on April 22 and 23, followed by events in the United Kingdom on April 28 and Switzerland on April 30. Held near the Belgium-Netherlands border, the Benelux event brought together healthcare practitioners from both markets, while the United Kingdom event welcomed medical professionals and industry stakeholders.

REJURAN’s global KOLs led the symposium sessions, presenting clinical results, treatment protocols and real-world case examples. The sessions covered the full REJURAN portfolio, including REJURAN for broader facial use, REJURAN I for thinner skin areas such as the eye area, and REJURAN S for wrinkle and scar-related applications.

The roadshow also served as a foundation for REJURAN’s broader growth in Europe. PharmaResearch completed its first shipment for the European market in January and has been building its local distribution network since then. Following positive early feedback, the company is expanding product supply and increasing its clinical education programs across the region.

Following the five-market Western Europe roadshow, PharmaResearch plans to continue the program in Italy in May, Poland in June and France in September. The company also plans to expand into Germany and other European markets in the second half of the year, further building REJURAN’s regional presence.

Vera Tual, Chief Customer Officer of VIVACY, PharmaResearch’s European partner, said, “Although REJURAN is still in the early stages of its European launch, HCP’s interest throughout the roadshow was strong. Attendees asked detailed questions about the product’s characteristics and practical applications, dsuggesting that REJURAN’s established reputation in Asia is helping build early momentum in Europe. The response also shows that REJURAN is quickly gaining attention among European HCPs as the new PN product for their aesthetic practices.”

She added, “REJURAN complements VIVACY’s existing aesthetics portfolio and gives us a valuable opportunity to engage with a wider network of medical professionals across Europe. We will continue to work closely with PharmaResearch to support the brand’s successful rollout in each market.”

A PharmaResearch representative said, “Interest in PN-based injectables is growing in Europe, but the market is still in its early stages. We see this as the right time to introduce REJURAN as a trusted PN-based skin booster backed by our DOT™ technology and clinical experience.”

The representative continued, “REJURAN is gaining traction in Europe faster than we expected. We believe this reflects the pre-existing global presence of REJURAN in the other markets, strength of our DOT™ technology, and the relevance of our product lineup for HCP. Based on the early response, we have raised our internal targets and will continue to expand distribution and education programs across Europe.”